Shilpa Medicare has been granted a patent for a process to prepare highly pure crystalline Bortezomib, a medication used in cancer treatment. The patent covers a specific crystalline form, SB-I, with distinct peaks and thermal properties. GlobalData’s report on Shilpa Medicare gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Shilpa Medicare, Nanoparticle drug conjugates was a key innovation area identified from patents. Shilpa Medicare's grant share as of May 2024 was 11%. Grant share is based on the ratio of number of grants to total number of patents.
Crystalline form of highly pure bortezomib
A recently granted patent (Publication Number: US11964993B2) discloses a crystalline form of bortezomib known as crystalline form SB-I. This form is characterized by specific peaks at 6.00, 12.07, 13.25, 18.72, 18.88, 19.13, 21.46, 23.66, 24.07, 24.46, and 25.97±0.2°, as well as an endothermic peak in the DSC isotherm between 101 to 103°C. These unique characteristics distinguish crystalline form SB-I from other forms of bortezomib.
Furthermore, the patent claims that the crystalline form SB-I of bortezomib has a specific water content range of 8 to 10% w/w based on the Loss on Drying method using thermo gravimetric analysis (TGA). This specific water content range further contributes to the distinct properties of crystalline form SB-I. Overall, the patent highlights the novel characteristics of this crystalline form of bortezomib, which could have implications for its use in various applications within the pharmaceutical industry.
To know more about GlobalData’s detailed insights on Shilpa Medicare, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.